Article Text

Download PDFPDF
724 Salpingectomy with delayed oophorectomy versus salpingo-oophorectomy in BRCA1/2 pathogenic variant carriers: three-year results regarding quality of life: an update of the TUBA study
  1. Miranda P Steenbeek1,
  2. Majke HDVan Bommel1,
  3. Joanna Inthout1,
  4. Marline G Harmsen1,
  5. Helena CVan Doorn2,
  6. Marian JE Mourits3,
  7. Rachel Tros4,
  8. Ronald P Zweemer5,
  9. Katja N Gaarenstroom6,
  10. Brigitte FM Slangen7,
  11. Monique MABrood-Van Zanten4,
  12. Caroline Vos8,
  13. Jurgen MJ Piek9,
  14. Luc RCWVan Lonkhuijzen4,
  15. Mirjam JA Apperloo10,
  16. Sjors FPJ Coppus11,
  17. Nicoline Hoogerbrugge1,
  18. Rosella PMG Hermens1 and
  19. Joanne ADe Hullu1
  1. 1Radboudumc, Nijmegen, The Netherlands
  2. 2Erasmus MC Cancer Clinic, Rotterdam, The Netherlands
  3. 3University Medical Centre Groningen, Groningen, The Netherlands
  4. 4Amsterdamumc, Amsterdam, The Netherlands
  5. 5UMC Utrecht Cancer Centre, Nijmegen, The Netherlands
  6. 6Leiden University Medical Centre, Leiden, The Netherlands
  7. 7Maastricht University Medical Centre, Maastricht, The Netherlands
  8. 8Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands
  9. 9Catharina Hospital, Eindhoven, The Netherlands
  10. 10Medical Centre Leeuwarden, Leeuwarden, The Netherlands
  11. 11Maxima Medical Centre, Veldhoven, The Netherlands


Introduction/Background Since most tubo-ovarian cancers originate in the fallopian tubes, the risk-reducing salpingectomy (RRS) with delayed oophorectomy (DO) was proposed as an alternative to risk-reducing salpingo-oophorectomy (RRSO). Compared to RRSO, menopause-related quality of life (QoL) appeared better after RRS up to one year post-surgery. We compare menopause-related QoL after RRS versus RRSO until three years post-surgery.

Methodology We performed a prospective multicenter preference study (TUBA study) among BRCA1/2 pathogenic variant (PV) carriers aged 25–40 (BRCA1) or 25–45 (BRCA2), who were premenopausal and without a future child wish. RRS could be performed from the age of 25 with DO at the maximum age of 45 (BRCA1) or 50 (BRCA2). RRSO could be performed between the ages of 35–40 (BRCA1) or 40–45 (BRCA2). After RRSO, hormone replacement therapy (HRT) was recommended, if not contraindicated.

Menopause-related QoL as measured with the Greene Climacteric Scale (GCS) was compared between the RRS and RRSO without HRT group. Secondarily, GSC-scores of the RRS group were compared with the scores of the RRSO with HRT after surgery group. A higher GSC-score reflects more climacteric symptoms.

Results Until April 2023, 410 participants had undergone RRS and 160 RRSO. The BRCA1/BRCA2 proportions were 51.4%/48.6%. The mean age at surgery (SD) was 37.9 (3.5) years. Participants three years after RRSO without HRT had a 4.3 (95% CI 2.1–6.5; p<.001) point higher increase in GCS-score from baseline compared to those after RRS, while the difference was 7.9 (5.9–9.8) and 8.5 (6.5–10.5) points at three and twelve months, respectively. Among participants with HRT after surgery, the RRSO group had a 2.4 (95% CI 0.8–3.9; p0.002) point higher increase in GCS-score from baseline compared to the RRS group.

Conclusion Menopause-related QoL is better after RRS than after RRSO, even with HRT after RRSO. Differences between arms were most pronounced until one year post-surgery.

Disclosures None of the authors have anything to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.